The FDA is being asked to either approve the therapy based on what numerous scientists say is an inconclusive record, or force Biogen to carry out another costly trial that could take years
The state-backed firm is to supply jabs that reduce the chances of children getting tuberculosis, measles and hepatitis B, among others
Life Healthcare CEO Shrey Virana talks to Business Day TV about its exit from Poland
Decision to divest highlights regulatory challenges that have confronted group and JSE-listed rivals
Netcare CEO Richard Friedland talks to Business Day TV about the group’s plans
SA's weak economy means and a growth in members covered by restricted hospital networks are expected to weigh on patient day growth
View is in contrast to the Hospital Association of SA which predicts that the current vision for universal coverage will cause extensive job losses
The group’s operating profit has surged 264% after it wrote down Hirslanden in the prior period
Sizwe has renegotiated fees with service providers from 2020 and drawn up ‘drastically changed’ agreements to stem its losses
Aspen CEO Stephen Saad talks to Business Day TV to discuss its plans to sell its Japanese business to a division of Novartis
The sale of its Japanese business to Sandoz is part of the pharma giant's strategy to shed noncore assets and reduce debt
Aspen has been disposing of assets to bring down debt, and want to sell its Japanese operations to Sandoz, a division of Switzerland-based Novartis
Dis-Chem CFO Rui Morais talks to Business Day TV about the pharmacy group’s expansion strategy and capital commitments
A global scare about the active ingredient ranitidine has triggered recalls around the world after being found to contain a carcinogen
The health group aims to sell off more businesses after suffering impairments totaling more than twice its market capitalisation
CEO Emma Walmsley has embarked on a plan to rejuvenate GSK, which has included the spin off or sale of some units since she took over in 2017
High cost of the largest US drugmaker's popular new heart medicine Vyndaqel, set to be the most expensive ever, faces criticism
Australian regulators order the recall of heartburn, acid reflux and ulcer medicine Zantac due to possible cancer risks
Private hospital group hedged the proceeds from the sale of Indian venture Max Healthcare, which cost it R406m
The drugmaker is banking on newer drugs to beat competition from cheaper generics
